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Abstract
The metabolism of gluconate is well characterized in prokaryotes where it is known to be degraded following
phosphorylation by gluconokinase. Less is known of gluconate metabolism in humans. Human gluconokinase activity was
recently identified proposing questions about the metabolic role of gluconate in humans. Here we report the recombinant
expression, purification and biochemical characterization of isoform I of human gluconokinase alongside substrate
specificity and kinetic assays of the enzyme catalyzed reaction. The enzyme, shown to be a dimer, had ATP dependent
phosphorylation activity and strict specificity towards gluconate out of 122 substrates tested. In order to evaluate the
metabolic impact of gluconate in humans we modeled gluconate metabolism using steady state metabolic network
analysis. The results indicate that significant metabolic flux changes in anabolic pathways linked to the hexose
monophosphate shunt (HMS) are induced through a small increase in gluconate concentration. We argue that the enzyme
takes part in a context specific carbon flux route into the HMS that, in humans, remains incompletely explored. Apart from
the biochemical description of human gluconokinase, the results highlight that little is known of the mechanism of
gluconate metabolism in humans despite its widespread use in medicine and consumer products.
Citation: Rohatgi N, Nielsen TK, Bjørn SP, Axelsson I, Paglia G, et al. (2014) Biochemical Characterization of Human Gluconokinase and the Proposed Metabolic
Impact of Gluconic Acid as Determined by Constraint Based Metabolic Network Analysis. PLoS ONE 9(6): e98760. doi:10.1371/journal.pone.0098760
Editor: Mark R. Muldoon, Manchester University, United Kingdom
Received December 19, 2013; Accepted May 6, 2014; Published June 4, 2014
Copyright:  2014 Rohatgi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the European Research Council grant proposal no. 232816. The funders had no role in study design, data collection and
analysis.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ottarr@hi.is
Introduction
Gluconate is a C-1 oxidized derivative of glucose, widely
distributed in nature and commonly used as an acidity regulator in
both food and drugs [1]. Gluconate is an excellent chelator of
calcium ions and calcium gluconate is often given intravenously in
order to regulate intravenous Ca2+ levels. While this clinical
measure undoubtedly focuses on replenishing Ca2+, gluconate and
its chemical counterpart gluconolactone against which it exists in
chemical equilibrium, have in fact been shown to exhibit
antioxidant properties and result in increased plasma levels of
glutathione [2]. Lowered plasma levels of gluconate have also been
associated with Alzheimer’s disease [3] and increased oxidative
stress [4].
We recently highlighted that gluconate metabolism in humans is
unaccounted for using a computational network gap filling
approach of the human metabolic network Recon 1. Gluconate
catabolism was computed to take place through phosphorylation
of gluconate to generate 6-phosphogluconate which could then be
further degraded through the hexose monophosphate shunt
(HMS) via 6-phosphogluconate dehydrogenase [5]. This catabolic
route has indeed been shown to take place in rat liver perfusions
[6] and corresponds to well researched degradation routes of
gluconate in microorganisms. These involve metabolism via (I)
direct internalization from the environment, (II) conversion from
L-idonic acid or (III) by direct oxidation of glucose via glucono-
1,5-lactone [7–9]. A key enzyme in all the gluconate degradation
routes is gluconokinase (GntK) which phosphorylates gluconate at
the C-6 position thereby priming its catabolism through the HMS
or the Entner-Doudoroff pathway in prokaryotes.
The human gene C9orf103 was identified through a metabolic
network gap filling effort of Recon 1 and through amino acid
sequence alignment as a likely kinase responsible for the initial step
in gluconate catabolism in humans [5]. C9orf103 had previously
been cloned and sequenced in relation to it being a plausible
tumor suppressor gene associated with acute myeloid leukemia
[10]. In vitro assays of isoforms I and II of C9orf103 expressed in
human HeLa cell lysates showed that only isoform I had ATP
dependant phosphorylation activity consistent with the absence of
a phosphate binding loop domain in isoform II. Isoform I shows
35% sequence similarity to both GntKs encoded within the E.coli
genome. A defining structural difference is an 18 amino acid insert
that is found in various NMP kinases that have similar protein
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structure to E.coli GntK and of which many are known and act on
a broad variety of substrates [5,11] (Figure 1A).
The presence of a functional human GntK is interesting.
Publically available expression and proteomic profiling datasets
show that human GntK is differentially expressed in the thyroid
and brain amongst others tissues [12,13]. This implies an
unknown or expanded role for the protein outside its proposed
catabolic role in the mammalian kidney and liver. Direct oxidation
of glucose to generate gluconate is generally not perceived to take
place in humans where phosphorylation precedes the oxidization
step. Excluding dietary origins, the metabolic origins of gluconate
remain unknown in humans. The notion that GntK activity is
encoded within the human genome however highlights a carbon
flux route into the HMS with possible implications for human
energy metabolism given the central role that the pathway plays in
fatty acid, nucleotide and amino acid synthesis and in combating
oxidative stress [14]. In order to further characterize human GntK
and gluconate metabolism, we report the expression, kinetic
characterisation and substrate specificity of a recombinant human
GntK isoform I expressed in E.coli. Furthermore, we assessed the
contribution of gluconate to human central metabolism through
constraint based modeling of the curated erythrocyte metabolic
model iARB-RBC-283 [15] and discuss its effect on human
metabolism.
Experimental
Expression and purification
Cloning expression and purification of C9orf103 was carried
out at the Center for protein research at the University of
Copenhagen. C9orf103 isoform I (BI826543, IMAGE ID:
5168613) was inserted into an in-house expression vector
pCPR0011 downstream of a 6xHIS and STREPII affinity tags
generating pCPR_GNTK-1 which, following sequence confirma-
tion, was transformed into Rosetta cells. The clone was inoculated
in 50 ml of TB media with kanamycin (50 mg/ml) and chloram-
phenicol (25 mg/ml) and incubated overnight at 37uC at 180 rpm.
7 ml of overnight culture was added to 750 ml of media with
kanamycin (50 mg/ml), and expression induced with 0.5 mM
IPTG at approximately OD600 = 1.5. Cells were then incubated
further at 18uC overnight and harvested by centrifugation at
4000 g for 10 min (culture OD600 = 13.5 at harvest). A 4.5 L
culture resulted in a 110 g cell pellet that was stored at 220uC
until purification at which point it was thawed, resuspended in
400 ml of running buffer (50 mM sodium phosphate, 0.3 mM
NaCl, 10 mM imidazole, 10% glycerol and 0.5 mM TCEP at
pH 7.5) containing protease inhibitors and benzonase, and lysed
using french press. The lysate was cleared by centrifugation at
18000 g for 30 min and filtered through a 0.22 mm filter and run
through a Nickel HiTrap column at a flow rate of 0.8 ml/min.
The protein was eluted off the column with running buffer
containing 0.5 M imidazole. Following dialysis and concentration,
the eluate was further purified using a 120 ml HiLoad 16/60
superdex 200 size exclusion column eluted with 50 mM sodium
phosphate, 150 mM NaCl, 10% glycerol, 0.5 mM TCEP, pH 7.5.
2 ml fractions were collected and samples pooled affording 14 ml
of 5.8 mg/ml protein using a calculated molar absorption
coefficient of 22461 Lmol21cm The enzyme was aliquoted and
stored in 280uC in 50 mM sodium phosphate, 150 mM NaCl,
10% glycerol and 0.5 mM TCEP at pH 7.5. PAGE was carried
out on NuPAGE 12% Bis-tris gels and NativePAGE 4–16%
Figure 1. Structural comparison of human GntK to E.coli GntK. A) An iTasser [44] structural model of human GntK (cyan) superimposed on
E.coli GntK (magenta) to which it shows 34% sequence homology. The 18 a.a. insert observed in human GntK is predicted to form a protruding a-
helix. B) SDS-PAGE of purified human GntK vs. E.coli GntK. C) Human GntK was observed to oligomerize as multiples of protein dimers. D) The
ionization pattern (inset) and deconvoluted mass spectrum of purified human GntK E) Circular dichroism spectra of the two proteins are indicative of
a similar tertiary structure.
doi:10.1371/journal.pone.0098760.g001
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Bis-Tris Gels using Novex Sharp pre-stained protein markers and
NativeMark unstained native markers as size markers, respective-
ly. Protein aliquots were removed from 280uC and thawed on ice
prior to enzyme assays. Loss of activity was not observed after
storage at 4uC for two weeks.
Circular Dichroism
Samples containing human GntK enzymes were dialyzed into
100 mM phosphate, 40 mM NaCl, 2.5 mM MgCl2 pH 7.2 and a
A J-810 CD spectrometer from Jasco (Tokyo, Japan) was used to
obtain CD spectra from 190 to 260 nm. For the Tm experiments,
the CD signal at 222 nm was monitored as the temperature
increased by 1uC/min. The protein concentration was in the
range 0.05–0.1 mg/mL.
Kinetic assays
The rate of gluconate phosphorylation was evaluated by
coupling GntK activity with that of 6-phosphogluconate oxidation
by 6-phosphogluconate dehydrogenase (6PGDH, Megazyme) and
monitoring the absorbance increase at 340 nm over time
corresponding to the accumulation of NADPH. Assays were
carried out in 100 mM phosphate, 40 mM NaCl, 2.5 mM MgCl2
pH 7.2 (Buffer A) taking into account assays reported by Leder
[16]. Glukonokinase was kept at 0.25 mM. 0.03 units of 6PGDH
were used per reaction. ATP final concentration was 1 mM and
gluconate concentration varied from 0.1–10 mM in order to
determine gluconate kinetic parameters but vice versa for ATP.
NADP+ concentration was 0.65 mM. Reactions were initiated by
addition of the target substrate. Reactions were carried out in 96
well clear, flat bottom plates and absorbance values were
correlated to NADPH concentration by extrapolation off a freshly
diluted NADPH standard curve. Initial reaction rates were
obtained from reaction progress curves and plotted against
substrate concentration and the resulting data fit to the Michaelis
Menten model using Softmax Pro. The values shown represent
average values from six biological replicates, performed in
technical triplicate.
Substrate specificity assays
Reactions were carried out in 96 well plates in buffer A with
ligand concentration at 0.5 mM, ATP at 0.1 mM and human
GntK at 250 nM in 50 ml total volume. Following a 30 min
incubation time at room temperature, ATP dependant phosphor-
ylation of substrates by human GntK was estimated by measuring
the drop in ATP concentration using the Promega Cell Titer Glo
assay according to the manufacturers’ protocol. Data is portrayed
as the difference in luminescence obtained for a substrate from the
average luminescence of all compounds. File S1 gives lumines-
cence values in each reaction subtracted from no GlcnK control
luminescence along with calculated z-scores and p-values for each
compound [17].
Modelling the uptake of gluconate metabolism in
erythrocytes
Modelling of gluconate metabolism was done using the
erythrocyte metabolic model iARB-RBC-283 [15] available
through the biomodels database as MODEL1106080000. iARB-
RBC-283 is a genome scale metabolic model generated and
curated by mining red blood cell literature and red cell proteomic
datasets. It represents the most complete representation of human
red cell metabolism in SBML format and is comprised of 283
genes, 267 unique small metabolites and 469 reactions. Gluconate
was introduced into the iARB-RBC-283 model by adding three
reactions, namely, for exchange, transport and for conversion of
D-gluconate to 6-phospho-D-gluconate using the COBRA toolbox
[18]. It is important to state that addition of the exchange and
transport reactions are only done in order to introduce gluconate
into the metabolic network so that the effect of varying
intracellular gluconate concentration on metabolism can be
modeled. Flux variability analysis (FVA) was utilized to determine
the changes in flux in reactions within the network. FVA calculates
the maximum and minimum possible flux through each reaction
under the given constraints [19]. A reaction was considered to be
effected if the change in the flux range upon gluconate
consumption was equal to or more than 40% of the flux range
in the absence of gluconate [15]. The flux range is the absolute
difference between the maximum and minimum fluxes of a
reaction. Flux variability analysis results are given in File S1 along
with calculated shadow prices of each reaction in iARB-RBC-283
in the presence and absence of the added gluconate reactions.
Shadow prices are indicator of how a metabolite affects the set
objective, which is to be maximized or minimized [20]. Flux
balance analysis, following relaxation of each transport reaction
bound are also given. All analysis of metabolic network properties
were carried out using the COBRA toolbox v.2.0 [18]. Abbrevi-
ations of all metabolites are according to the BiGG database [21].
Results
Characterisation of human GntK
Human GntK was over expressed and purified as described in
materials and methods. The vector construct expressed a protein
product of 208 a.a. compared to the 187 a.a. residue wild type
protein due to N-terminal hexahistidine and strep tags. SDS-
PAGE showed the protein to be more than 95% pure and
migrated to a similar extent as commercially available E.coli GntK
(Figure 1B). Both of these were immunogenic towards a
polyclonal antibody against human GntK. The major band
migrated with an observed molecular mass of 21,82560.7 Da
having a calculated mass of 23,326 Da. This corresponds well with
the mass spectrometry result of 23,325.2 Da (Figure 1C). Native
gel electrophoresis showed that the protein exists as dimers and
oligomerizes as such. The calculated molecular weight of the two
most prominent bands in lanes 4 and 5 in Figure 1D were
41.78561.9 kDa and 85.0363.3 kDa corresponding to a GntK
dimer and tetramer. The E.coli GntK was similarly observed to
oligomerize as multiples of dimers and has been shown to exist as a
homodimer in solution [8]. The circular dichroism spectra, an
indicator of protein secondary structure [22], of the recombinant
forms of both GntKs was similar. Defining negative bands at
208 nm and 222 nm were observed indicative of an a-helical
structure although differences were seen in their intensities hinting
at conformational differences. A negative band was observed in
the human GntK at 200 nm which was not observed in the E.coli
GntK a difference that was accredited to the unstructured N-
terminal region containing the His and Strep tags.
Kinetics of GntK
The steady state kinetics of GntK was investigated by coupling
6-phosphogluconate formation to consumption by 6-phosphoglu-
conate dehydrogenase and measuring the resulting increase in
NADPH formation spectrophotometrically at 340 nm (Figure 2).
Initial rates were calculated and plotted against substrate concentra-
tion and the resulting data fit to the Michaelis Menten equation. A
double reciprocal plot of initial reaction rates at varied gluconate and
ATP concentrations, respectively, is shown in Figure 2B. The
experimental kinetic parameters for phosphorylation of gluconate
Human GNTK and Its Proposed Metabolic Impact
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are given in Table 1. The affinity of the GntK for gluconate was
roughly 3 times that for ATP while the turnover numbers for both
substrates were the same. Phosphorylation of gluconate by the
nucleoside triphosphates GTP, CTP and UTP was observed. The
kinetic parameters for these were not accurately determined. Initial
rate data however implied that the Michaelis constant for UTP is
roughly five orders of magnitude higher than that of ATP and ten
orders higher for GTP and CTP. Nucleotide hydrolysis in the
absence of gluconate was not detected.
Substrate specificity of GntK
The annotation of C9orf103 encoding GntK activity was tested
further by investigating substrate dependent ATP phosphorylation
against an in-house metabolic library composed of a broad
spectrum of metabolites involved in core metabolism (Figure 3).
Following incubation of human GntK with the substrates at a
fixed ATP concentration, the drop in ATP concentration was
detected spectrophotometrically. The enzyme showed little activity
above background for any of the substrates tested apart from
gluconate and glucono-1,5-lactone. Included in this list were
twenty five carbohydrate/carbohydrate conjugates and twenty
four organic acids, including known substrates of closely related
carbohydrate kinases [23] such as D-ribulose, meso-erythrose and
glycerol. A full list of all compounds screened is given in File S1.
The effects of gluconate on core metabolism
Flux variability analysis of the erythrocyte metabolic model iAB-
RBC-283 [15] was utilized in order to evaluate changes in cellular
core metabolism induced by gluconate degradation. Gluconate
was fed into the HMS via 6-phosphogluconate by relaxing the
bounds on exchange for gluconate at a fixed glucose uptake rate of
1.12 mmol/gDW/h [24]. This resulted in a 0.06 mmol/gDW/h
flux increase through the ATP dependent Na2+/K+ pump that was
set as the objective function. The flux through GntK spanned
0.20–4.46 mmol/gDW/h. An increase in the flux range of all
reactions in both the HMS and glycolysis was also observed upon
uptake of gluconate (Figure 4a). Accordingly, production of
NADPH increased that in turn increased production of reduced
glutathione and flux through reactions associated with fatty acid
metabolism in the model. As glycolysis is interconnected to the
HMS, this also led to increased pyruvate and lactate production.
In fact, flux ranges for roughly 80% of all the reactions in the
metabolic network were perturbed upon gluconate metabolism by
more than 40% of the initial flux range in the absence of
gluconate. Out of the reactions showing a change in flux ranges,
multiple reactions were activated in the presence of gluconate
meaning that no flux through these reactions takes place prior to
gluconate metabolism in the metabolic model (Figure 4b).
The effect of GntK flux on the objective was investigated further
employing robustness analysis. Flux balance analysis was per-
formed at forced and increasing rates (0–20 mmol/gDW/h) of
gluconate uptake, at a fixed glucose uptake rate of 1.12 mmol/
gDW/h [24] (Figure 5). As expected, based on the FVA analysis,
the objective maximum was reached at a flux of 0.2 mmol/gDW/
h through GntK, which is roughly 18% of the set glucose uptake
rate. Increasing the GntK flux rate past 4.5 mmol/gDW/h
resulted in a sharp drop in the objective as metabolites required
for gluconate catabolism became limiting due to physiologically
determined model constraints [24]. In order to pinpoint these
metabolites we calculated shadow prices for each metabolite in the
metabolic network in the presence and absence of gluconate (File
S1). In the absence of gluconate, 89 out of the 267 unique
metabolites within iAB-RBC-283 had an effect on flux through the
ATP dependent Na2+/K+ pump while in the presence of
gluconate this number was reduced to 10. These metabolites
were all ultimately associated with either bicarbonate transport/
exchange (bicarbonate, chloride, potassium, bilirubin monoglu-
curonide, bilirubin, biliverdin and carbon monoxide) or glutathi-
one synthesis (L-cysteine, c-L-glutamyl-L-cysteine and glycine) and
became limiting on the account of increased levels of NADPH and
carbon dioxide generated from gluconate catabolism.
Further investigation into the limiting factor of gluconate
metabolism was performed by relaxing bounds constraining each
exchange reaction followed by flux variability analysis (File S1). In
the absence of gluconate, a total of 7 reactions, including exchange
of glucose, galactose, glucosamine mannose, fructose, inosine and
adenosine were observed to affect the objective function. In the
presence of gluconate however there was only one reaction,
namely bicarbonate exchange. The modeling results indicate that
metabolism of gluconate via the HMS compensates for the
aforementioned metabolites. This occurs until transport of
bicarbonate, generated from increased levels of carbon dioxide
Figure 2. Reaction kinetics of the phosphorylation of gluconate
by human GntK. A) Reaction progression curves at increasing
gluconate concentration. Initial rates were plotted against substrate
concentrations and fit to the Michaelis Menten model using nonlinear
regression to afford kinetic parameters shown in Table 1. B) Double
reciprocal representation of the kinetic data.
doi:10.1371/journal.pone.0098760.g002
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that in turn originate from increased dehydrogenase activity, limit
metabolism.
Discussion
Gluconate metabolism is well characterized in microorganisms
due to bioengineering efforts to enhance production of gluconate
for industry. In humans, studies have been carried out that have
shown the compound to be safe and degraded via core metabolic
pathways [25]. Crucially, Stetten demonstrated that gluconate is
metabolized differently than glucose in rats and contributes to
glycogen and CO2 production [6]. In humans however gluconate
metabolism remains under-explored in light of its potential role in
metabolism. The molecular details of gluconate metabolism and
how it might contribute to energy metabolism have not been
characterized in humans. Here we employed a combined
approach composed of traditional molecular biology and compu-
tational network modeling methods to gain information on GntK
and gluconate metabolism in humans, respectively. We charac-
terized isoform I of human GntK in terms of structure, kinetic
properties and substrate specificity. Metabolic network analysis,
designed to afford ideas on the contribution of gluconate to core
metabolism was performed on the genome scale metabolic
network iAB-RBC-283 encompassing red cell metabolism. These
show that combined glucose and gluconate metabolism is likely to
result in beneficial effects on cellular anabolism.
Isoform I of human GntK was characterized in terms of
structure, kinetic properties and substrate specificity. Denaturing
gel electrophoresis and mass spectrometry confirmed the purity
and identity of the recombinant enzyme which was shown to
conform to a dimer structure using native gel electrophoresis
(Figure 1). Indeed, many of the carbohydrate kinases including,
glycerol kinase, shikimate kinase, xylulokinase and GntK are
known to be active as dimers [23] and this appears to be the case
for human GntK as well. The 18 a.a. insertion found in human
GntK which is likely the defining structural difference between
human GntK and prokaryotic GntK, does therefore not affect the
dimerization properties of the enzyme. This corresponds with the
electronic structural proposal of human GntK indicating that the
insert is located away from the dimer interaction interface of the
protein. We obtained CD spectra, a method for determining the
secondary structure of proteins [22]. The CD spectra of GntK and
E.coli GntK provided further confirmation of structural similarities
and suggested that the enzyme most likely adheres to the a/b
structure and topology solved for E.coli GntK. More focused
Table 1. Human GntK kinetic properties.
Km (mM) Vmax (mM/s) kcat (s
21) kcat/Km (s
21mM21) R2
Gluconate 106.4618.5 2.360.1 9.360.5 0.08960.013 0.9860.008
ATP 343.8613.9 2.460.1 9.560.5 0.02860.002 0.9960.002
doi:10.1371/journal.pone.0098760.t001
Figure 3. Human GntK showed strict substrate specificity for D-gluconate out of 122 common metabolites involved in human core
metabolism. Activity was only observed for D-gluconate and its lactone derivative. These had calculated p-values of 9.5610217 and 3.4610212
based on Z-scores of 28.2 and 26.7 respectively. The pie chart shows the number of compounds tested according to their taxonomy class.
doi:10.1371/journal.pone.0098760.g003
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structural biology methods are however required to deduce the
fine details of the structure of human GntK.
Apart from non-cognate GntKs, human GntK shows sequence
similarity to various NMP kinases known to catalyze the
phosphorylation of a broad range of substrates [11]. We found
that recombinant human GntK showed strict substrate specificity
for gluconate. ATP dependant phosphorylation activity was also
observed for glucono-1,5-lactone as it exists in equilibrium with
gluconate in aqueous conditions. The enzyme was inactive against
the hexoses D-glucose, D-galactose, D-fructose, D-mannose and
D-glucosamine. Similarly no activity was observed against the
pentoses D-ribose, D-ribulose, D-arabinose, D-xylulose, D-xylose
and D-erythrose. Finally no activity was observed against various
polyols and carboxylic acids which differ from gluconate in terms
of carbon chain length and in their degree of saturation.
Previously, for hog GntK, substrate specificity analyses were
focused on compounds similar in structure to gluconate. The
substrates tested in this study were structurally more diverse. These
results refute automated electronic annotations of this enzyme
having shikimate kinase and adenylate kinase activity and imply
that the phosphorylation activity of human GntK is indeed specific
for gluconate. This is in line with the findings for hog GntK [16]
and the constraints on substrate binding implied from the crystal
structure solved for E.coli GntK [11].
The estimated Michaelis constant obtained for human GntK
towards gluconate was similar to that found for hog GntK,
Km=140 mM, but higher than those reported for E.coli GntK,
Km=20 mM [8,9]. The ratio of Kmglcn/KmATP is however similar
between human GntK and E.coli GntK, 3.2 vs. 3.0 and implies
that the reaction dynamics are similar for these enzymes. The
turnover numbers for both gluconate and ATP were nearly
identical (Table 1) however the catalytic efficiency (kcat/Km) for
gluconate was slightly higher than for ATP indicative of a
sequential reaction mechanism. The order of substrate binding
was however not determined. The reaction mechanism for GntK
from E.coli and S. pombe have been proposed, and while both found
that the reaction takes place via a transition state following
sequential binding, the binding order of substrates was proposed to
be ordered for E.coli GntK as opposed to random for S.pombe
GntK. The results reported here do not allow the reaction
Figure 4. Modelling the contribution of gluconate to core metabolism. A) Metabolic flux through glycolysis and the HMS is affected upon
gluconate (yellow) consumption via GntK. The two added reactions (grey) feed gluconate into the HMS as described in the text. Reactions in the HMS
and glycolysis with changed flux ranges upon gluconate uptake are indicated by arrow thickness as defined in File S1. Metabolite abbreviations are
consistent with the BiGG database. B) Flux variability analysis showed changes in the flux ranges of 329 out of the 416 reactions in the RBC model
upon incorporation of gluconate. 56 miscellaneous reactions, which were not defined properly in the model, have been removed from this graph to
simplify the graph. Gluconate degradation also activated reactions that otherwise did not carry flux due to constraints imposed by flux into the HMS
through glucose-6-phosphate dehydrogenase which was floated at physiological 5–10% of glucose uptake.
doi:10.1371/journal.pone.0098760.g004
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mechanism for human GntK to be determined. A detailed report
on the kinetics and thermodynamics of the human GntK reaction
will be reported separately.
The only reported degradation route of gluconate in vertebrates
is via the HMS [16,26,27]. In order to assess how gluconate
contributes to global metabolism, its degradation through the
HMS was modeled using FVA of the erythrocyte metabolic model
iAB-RBC-283. Although human genome scale cell and tissue
specific metabolic models have been generated for a variety of
context specific applications [28–32], this model was chosen to
model metabolism for several reasons. Firstly the model is small
with few components, uncluttered with minimum possibilities of
false positives introduced by metabolic gaps, dead ends and flux
loops [30,33,34] and the model has defined metabolite exchange
constraints [15]. Secondly the Na+/K+ pump is a realistic
objective function, the maintenance of the Na+ concentration
gradient has been shown to account for up to 70% of cell ATP
expenditure [35]. Finally, erythrocytes have a very active HMS so
any observed flux changes were likely to be emphasized with a
minimum of false positives. A drawback of this model is the
absence of core metabolic pathways downstream of glycolysis
namely the TCA cycle and oxidative phosphorylation that are
indeed central to cells that carry out aerobic glycolysis.
Introducing gluconate had an effect on flux through reactions
within the model. 269 reactions were activated and 60 reactions
showed changes in their flux range out of a total of 472 reactions in
iAB-RBC-283. In the HMS, 9 out of 10 reactions had increased
flux ranges, however the biggest effect was observed in metabolic
pathways involving metabolites/reactions derived from the HMS.
These included nucleotide, carbohydrate, amino acid and lipid
metabolic pathways due to increased levels of ribose-5-phosphate,
xylulose-5-phosphate, erythrose-4-phosphate and NADPH, re-
spectively. This suggests that the metabolic repertoire/capacity of
the model is significantly increased upon gluconate degradation.
Increasing flux through the HMS in the form of gluconate relieves
constraints on these pathways imposed by the glucose uptake rate
and the HMS split ratio. Indeed a similar effect would be observed
if the flux into the HMS would be increased through glucose-6-
phosphate dehydrogenase. In erythrocytes glucose-6-phosphate
deyhydrogenase is the main source of NADPH and is the most
common enzyme deficiency known and has deleterious effects
when homozygous [36]. The modeling results here simply
demonstrate that considerable control of key metabolic pathways
can be achieved by bypassing this regulatory enzyme into the
HMS. There is little apparent energetic gain to feeding the HMS
through GntK or through hexokinase. Both pathways supposedly
result in the same use and production of ATP and NADPH. We
propose that GntK or enzymes upstream of it are involved in
context specific regulation of carbon flux into the HMS. A gene
co-expression analysis or knockdown study of the effect of GntK
on core metabolism could help shed light on a novel flux route into
the HMS in humans.
There are several ways in which gluconate could be generated
endogenously. It could be formed by spontaneous oxidation of
glucose, as a product of advance glycation end-product formation
[37], as a product of microbiota [38], through undiscovered
anabolism of complex glycans or simply by dephosphorylation of
6-phosphogluconate. In these cases GntK might function as a
salvaging enzyme, re-routing gluconate back into central carbon
metabolism through the HMS. Another route of gluconate
formation is its production through direct oxidation of glucose
via glucose dehydrogenase (EC 1.1.1.47) and gluconolactonase
(EC 3.1.1.17). Glucose dehydrogenase activity is not generally
believed to be a central part of human metabolism. Although the
endoplasmic reticulum localized hexose-6-phosphate dehydroge-
nase has been reported to carry out the direct oxidation of glucose,
generating D-glucono-1,5-lactone, its main substrate is glucose-6-
phosphate [39,40]. D-gluconolactonase activity, affording gluconate
Figure 5. Robustness analysis of gluconate flux through GntK vs. the Na2+/K+ transporter pump set as the objective in iAB-RBC-283.
A slight increase in flux through the Na2+/K+ transporter pump that then became constant up to a gluconate flux rate of 4.5 mmol/gDW/h was
observed upon gluconate addition. This resulted in an increase (defined as .40%) in the flux range of multiple reactions in iAB-RBC-283. At GntK flux
rates above 4.5 mmol/gDW/h bicarbonate exchange becomes limiting and as a result flux through the Na2+/K+ transporter pump drops. The figure
inset is the same as the above but with a modified scale.
doi:10.1371/journal.pone.0098760.g005
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from D-glucono-1,5-lactone, has been shown to be encoded by the
microsomal enzyme SMP30 in the context of ascorbic acid synthesis
in rats [41]. Given that humans do not synthesize ascorbic acid it is
likely that SMP30 has a different metabolic role in humans. In an
attempt to address this, over expression of SMP30 in HEPG2 cells
has been shown to result in significant reduction in reactive oxygen
species with associated decreases in lipid peroxidation levels and
superoxide dismutase activity. The effects were attributed to
intracellular [Ca2+] modulation brought about by increased
SMP30. SMP30 itself was shown not to have radical scavenging
ability and Handa et al. proposed an indirect antioxidant ability of
SMP30 [42]. In light of our modeling results, which indicate how
human GntK activity affects the global metabolic phenotype, we
propose that the effect observed upon SMP30 over expression and
later complemented by knockdown experiments of SMP30, is
brought about by modulating flux into the HMS through gluconate
thereby promoting NADPH formation.
Herein we have described the biochemical characterization of
human GntK, an enzyme flagged in two network gap filling
analyses of Recon 1 [5,43] and employed constraint based
network analysis to assess how gluconate might impact human
metabolism. The results advance knowledge of the biochemical
properties of isoform I of human GntK and suggest that
considerable perturbation of metabolic pathways associated with
the HMS result given that gluconate degradation follows similar
routes in humans as reported in vertebrates. Furthermore, these
data serve to highlight an overlooked carbon flux pathway into the
HMS in humans which could be of significance given the
pathways central anabolic role and importance in combating
oxidative stress. Finally the results demonstrate the application of
human metabolic models to assess metabolic phenotypes and how
these can be put into context with existing biological data to
advance functional genomic hypotheses.
Supporting Information
File S1 The file contains five worksheets that report the
following 1: measured luminesence values from the substrate
specificity assays 2: results from flux variability analysis of in iAB-
RBC-283 with and without gluconate. 3: how flux values relate to
arrow thickness as portrayed in figure 4. 4: Calculated shadow
prices in the presence and absence of gluconate. 5: FBA solutions
obtained upon relaxing transport/exchange flux boundaries in the
presence and absence of gluconate.
(XLSX)
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